Three milestones expected to bring the reality of U.S. prescription drug price negotiations into focus are hovering on the horizon. First, the CMS is scheduled to publish its maximum fair prices (MFPs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback